Gilead Class Action Lawsuit: TDF Claims, Defenses, and Settlements

The Gilead class action lawsuit most people are asking about is the mass product liability litigation over the company’s HIV medications containing tenofovir disoproxil fumarate, or TDF. More than 24,000 plaintiffs allege Gilead Sciences knew about a safer version of the drug, called tenofovir alafenamide (TAF), and deliberately delayed bringing it to market to keep selling TDF-based products. The cases are consolidated in San Francisco Superior Court and are currently on hold while the California Supreme Court decides whether a drugmaker can be sued for not developing a safer alternative fast enough. Gilead also faces or has resolved several other lawsuits, including a $202 million federal kickback settlement, a $4 million privacy breach settlement, antitrust claims, and a Canadian national class action.¹

What the TDF Lawsuits Allege

Five Gilead HIV drugs are at the center of the injury litigation: Viread, Truvada, Atripla, Complera, and Stribild. All contain TDF, which the FDA first approved in 2001. TDF converts to its active form in the bloodstream, exposing the kidneys and bones to relatively high levels of the drug. The approved labels warned of potential kidney damage and bone density loss, and neither side disputes those risks exist.¹

Plaintiffs say they developed those exact injuries after years on TDF drugs, including kidney failure, bone fractures, osteoporosis, osteopenia, and in some cases Fanconi syndrome, a serious kidney disorder.² The lawsuits do not claim TDF was mislabeled or that its risks were hidden. They claim Gilead had something better on the shelf.

That something is TAF. While developing TDF in the late 1990s, Gilead also discovered TAF, which is metabolized inside cells instead of in the bloodstream. Less of the drug circulates through the body, so less reaches the kidneys and bones.³ Early testing in 2002 suggested TAF might have fewer side effects.⁴

In 2004, Gilead publicly announced it was discontinuing TAF research. Plaintiffs allege that decision was made to protect the TDF franchise from competition by Gilead’s own superior product. One lawsuit alleged that between October 2004 and May 2005, while publicly saying it had dropped TAF, Gilead quietly filed seven TAF-related patents.⁵ Gilead resumed TAF research in 2010. Phase III trials in 2013 showed TAF caused less kidney and bone harm than TDF. The FDA approved TAF-based drugs in 2015, more than a decade after the pause.⁴

How Gilead Is Defending the Cases

Gilead’s central factual argument is that when it paused TAF development in 2004, only one small human trial had been completed, involving 20 patients over two weeks, and those results showed similar safety profiles for both drugs. TAF had never reached Phase III trials, and its long-term safety was unknown.⁶

On the law, Gilead argues that no court in California or anywhere else has held a manufacturer liable for injuries caused by a non-defective product. Because plaintiffs concede TDF was not defective and its warnings were adequate, Gilead calls the theory an unprecedented “duty to innovate” that would discourage pharmaceutical research. The company also raised a federal preemption defense, arguing FDA approval of TDF shields it from state tort claims. A California appellate court unanimously rejected that preemption argument in January 2024.⁷

Where the Cases Stand Now

The bulk of the litigation, more than 24,000 plaintiffs, sits in San Francisco Superior Court under JCCP No. 5043 before Judge Andrew Y.S. Cheng. Fourteen individual cases were designated for bellwether trials to test the strength of the claims.⁸

Before those trials could produce results, the California Court of Appeal issued a split ruling in January 2024. The court allowed the core negligence claim to proceed, holding that a manufacturer’s duty of reasonable care can extend beyond simply not selling a defective product. But it sided with Gilead on fraudulent concealment, ruling the company had no legal duty to disclose information about TAF, an unapproved drug not yet on the market, to patients taking TDF.⁷

In May 2024, the California Supreme Court agreed to review the case, docketed as No. S283862. The question: does a manufacturer have a legal obligation to continue developing a new, potentially improved product while marketing an existing, non-defective one?⁹ Twelve amicus briefs with 67 signatories were filed backing Gilead, including from the U.S. Chamber of Commerce, the California Chamber of Commerce, the Washington Legal Foundation, and the National Retail Federation.¹⁰

Oral argument was held on May 6, 2026. As of mid-2026, the case has been submitted for decision but no ruling has been issued. The court typically issues opinions within 90 days of argument.⁹

The Federal Settlement

In June 2024, Gilead reached an agreement in principle to pay up to $40 million to resolve about 2,625 cases pending in federal court. That works out to roughly $15,000 per plaintiff before attorneys’ fees, a figure widely seen as reflecting lower-severity claims rather than the full value of the litigation.¹¹ The deal required participation from at least 98% of eligible plaintiffs, and Gilead characterized it as carrying no admission of wrongdoing.¹²

That settlement does not apply to the far larger pool of state-court cases. Gilead has signaled it will not negotiate over the California cases until the Supreme Court rules.¹³

Other Gilead Lawsuits

The $202 Million Kickback Settlement

In April 2025, Gilead agreed to pay $202 million to resolve a federal civil fraud lawsuit alleging the company paid kickbacks to doctors to boost prescriptions of its HIV drugs between 2011 and 2017. U.S. District Judge Paul A. Engelmayer approved the settlement, which resolved claims brought by the U.S. Department of Justice, the HHS Office of Inspector General, the FBI, and 49 states.¹⁴

Gilead admitted to using “HIV Speaker Programs” to funnel money to high-volume prescribers. One doctor received more than $300,000 in speaking fees, generating over $6 million in billings to federal healthcare programs. Events were held at high-end restaurants with multi-course meals and alcohol, and some included travel to Hawaii and Miami. Some prescribers attended the same program topic three or more times within six months. The drugs involved were Stribild, Genvoya, Complera, Odefsey, Descovy, and Biktarvy, distinct from the TDF injury litigation.¹⁴

The Privacy Breach Class Action

Gilead’s Advancing Access patient assistance program sent 9-by-12-inch envelopes to more than 18,000 enrollees with “HIV Prevention Team” printed in bold red font on the return address, disclosing participants’ HIV-related medication use to anyone who saw the mail. The medications were Truvada and Descovy, both used for pre-exposure prophylaxis (PrEP).¹⁵

Gilead settled the case, Alabama Doe, et al. v. Gilead Sciences, Inc., for $4 million. The court granted final approval in July 2023, with distribution beginning the following month. Class members received a minimum of $100 each, with additional payments of up to $500 for emotional distress and up to $2,000 for documented out-of-pocket expenses such as moving costs or lost income. A second and final distribution followed in late 2024.¹⁵

Antitrust Litigation Over Generic Delays

Plaintiffs in In re HIV Antitrust Litigation (Case No. 3:19-cv-02573, Northern District of California) alleged Gilead struck a 2014 “reverse payment” deal with generic maker Teva to delay generic Truvada and Atripla, resulting in $3.6 billion in overcharges.¹⁶ Wholesale drug purchasers settled with Gilead for $247 million, with final approval in January 2024.¹⁷ A separate group of insurers and health plans went to trial and lost in mid-2023, with the jury finding Gilead did not have market power and had not made an illegal reverse payment.¹⁸

The Canadian Class Action

In April 2021, Klein Lawyers filed a class action in British Columbia on behalf of Canadians who took the same five TDF-based drugs, mirroring the U.S. claims.³ On March 22, 2024, the B.C. Supreme Court certified the case as a national class proceeding covering Canadians across the country.¹⁹ Gilead has appealed the certification, and as of mid-2026 no hearing date has been set.

What Happens Next for Plaintiffs

The TDF product liability litigation hinges almost entirely on the California Supreme Court’s pending decision. If the court upholds the appellate ruling that manufacturers can owe a duty of care to develop safer alternatives, the 24,000 state-court cases will move toward bellwether trials and likely large-scale settlement talks. If the court rejects the duty-to-innovate theory, plaintiffs lose the legal foundation for their claims and the litigation could effectively end. Gilead has declined to negotiate over the state cases while the court deliberates, so for the thousands of plaintiffs who say TDF damaged their kidneys and bones during a decade when something better existed, the wait continues.

1
Gilead Sciences. TDF Litigation
2
AboutLawsuits.com. HIV Drug Lawsuits
3
Klein Lawyers. TDF Drug Injury
4
FDLI. Gilead Tenofovir Cases
5
Fierce Pharma. Gilead Shelved Safer HIV Drugs for Years, Patients Say
6
King & Spalding. Duty to Innovate: California Supreme Court Questions Novel Product Liability Theory
7
FindLaw. Gilead Life Sciences v. The Superior Court of San Francisco
8
Lieff Cabraser. Gilead HIV Drugs Litigation
9
GMSR. Gilead Tenofovir Cases, S283862
10
U.S. Chamber of Commerce. Amicus Brief in Gilead Sciences v. Superior Court
11
San Francisco Chronicle. Gilead Settlement
12
Fierce Pharma. Gilead Offers $40M to Settle Federal Claims
13
Wallace Miller. TDF Tenofovir Litigation
14
U.S. Attorney’s Office, SDNY. U.S. Attorney Announces $202 Million Settlement With Gilead Sciences
15
AIDS Law Project of Pennsylvania. Alabama Doe and Indiana Doe v. Gilead Sciences, Inc.
16
WSGR. Jury Finds Gilead and Teva Did Not Engage in Anticompetitive Pay-for-Delay Scheme
17
Law360. In re HIV Antitrust Litigation
18
Proskauer. Proskauer Secures Significant Victory for Gilead Sciences
19
Vancouver Sun. B.C. Class Action Lawsuit Against HIV/AIDS Drugmaker Gilead